Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tazemetostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fulcrum Halts Pociredir In Sickle Cell, Starts Strategic Review
    Fulcrum Halts Pociredir In Sickle Cell, Starts Strategic Review

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304708/0/en/fulcrum-therapeutics-announces-discontinuation-of-pociredir-program-in-sickle-cell-disease-and-initiation-of-strategic-review.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Ipsen Withdraws Tazverik In Lymphoma And Sarcoma
    Ipsen Withdraws Tazverik In Lymphoma And Sarcoma

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251503/0/en/Ipsen-voluntarily-withdraws-Tazverik-tazemetostat-in-follicular-lymphoma-and-epithelioid-sarcoma.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    HUTCHMED Updates On TAZVERIK Oncology Product In China
    HUTCHMED Updates On TAZVERIK Oncology Product In China

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251601/0/en/HUTCHMED-Announces-Update-on-Licensed-Oncology-Product-TAZVERIK-in-China.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201158/0/en/HUTCHMED-Announces-Expanded-Coverage-on-National-Reimbursement-Drug-List-and-Inclusion-in-the-First-Commercial-Insurance-Drug-List-in-China.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    Hutchmed: NMPA Approves TAZVERIK® for Follicular Lymphoma
    Hutchmed: NMPA Approves TAZVERIK® for Follicular Lymphoma

    21 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/21/3046949/0/en/HUTCHMED-Announces-NMPA-Conditional-Approval-for-TAZVERIK-tazemetostat-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma.html

    GLOBENEWSWIRE
    21 Mar 2025
    Share Share
    Hutchmed's NDA For Tazemetostat In Follicular Lymphoma Accepted In China
    Hutchmed's NDA For Tazemetostat In Follicular Lymphoma Accepted In China

    03 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/04/2908483/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Tazemetostat-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-Lymphoma-with-Priority-Review-Status.html

    GLOBENEWSWIRE
    03 Jul 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.